Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines

Article

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

Samsung Biologics has signed a memorandum of understanding (MOU) with Sartorius to further strengthen the supply chain for biomedicines. The MOU follows a recent announcement by Sartorius that the company plans to invest $100 million in South Korea's bio cluster, Songdo, to build a bioprocess manufacturing facility for equipment and materials, Samsung Biologics announced in a Nov. 16, 2020 press release.

Sartorius plans to supply materials such as disposable bags, cell culture media, and filters to Samsung Biologics. The facility will be built on a 24,333-m2 site in Songdo. Construction is expected to be completed by 2022.

Source: Samsung Biologics

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.